Abnormal visual activation in Parkinson's disease patients

Movement Disorders

Volumn 25, Issue 11, 2010, Pages 1590-1596

  Cardoso, Ellison Fernando ^a   Fregni, Felipe ^b   Maia, Fernanda Martins ^a   Melo, Luciano M ^a   Sato, João R ^a,c   Cruz Jr , Antonio Cesário ^a   Bianchi, Edno Tales ^a   Fernandes, Danilo Botelho ^a   Monteiro, Mário Luiz Ribeiro ^a   Barbosa, Egberto Reis ^a   Amaro Jr , Edson ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSIDADE FEDERAL DO ABC   (Brazil)

Author keywords

Dopamine; fMRI; Hallucinations; Parkinson's disease; Visual symptoms

Indexed keywords

AMANTADINE; BIPERIDEN; BROMOCRIPTINE; LEVODOPA; PRAMIPEXOLE; SELEGILINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EVOKED VISUAL RESPONSE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PRIORITY JOURNAL; SYMPTOM; VISION; VISUAL CORTEX; VISUAL HALLUCINATION; VISUAL STIMULATION;

AGED; ANALYSIS OF VARIANCE; FACE; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TESTS; OXYGEN; PARKINSON DISEASE; PATTERN RECOGNITION, VISUAL; PERCEPTUAL DISORDERS; PHOTIC STIMULATION; STATISTICS AS TOPIC; VISUAL CORTEX; VISUAL PATHWAYS;

EID: 77955834765     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23101     Document Type: Article

References (36)

1. Silva MF, Faria P, Regateiro FS. Independent patterns of damage within magno-, parvo- and koniocellular pathways in Parkinson's disease. Brain 2005;128 (Part 10):2260-2271. (Pubitemid 41407966)
2. Antal A, Pfeiffer R, Bodis-Wollner I. Simultaneously evoked primary and cognitive visual evoked potentials distinguish younger and older patients with Parkinson's disease. J Neural Transm 1996;103:1053-1067. (Pubitemid 26383835)
3. Cardoso EF, Fregni F, Martins Maia F. rTMS treatment for depression in Parkinson's disease increases BOLD responses in the left prefrontal cortex. Int J Neuropsychopharmacol 2008;11:173-183.
4. Fregni F, Santos CM, Myczkowski ML. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2004;75:1171-1174. (Pubitemid 39005779)
5. Talairach J, Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain, New York: Thieme; 1998.
6. Brammer MJ, Bullmore ET, Simmons A. Generic brain activation mapping in functional magnetic resonance imaging: a nonparametric approach. Magn Reson Imaging 1997;15:763-770. (Pubitemid 27398247)
7. Bullmore E, Fadili J, Breakspear M, Salvador R, Suckling J, Brammer M. Wavelets and statistical analysis of functional magnetic resonance images of the human brain. Stat Methods Med Res 2003;12:375-399. (Pubitemid 37368967)
8. Hayasaka S, Nichols TE. Combining voxel intensity and cluster extent with permutation test framework. Neuroimage 2004;23:54-63.
9. Matsui H, Nishinaka K, Oda M. Depression in Parkinson's disease. Diffusion tensor imaging study. J Neurol 2007;254:1170-1173. (Pubitemid 350112338)
10. Brandies R, Yehuda S. The possible role of retinal dopaminergic system in visual performance. Neurosci Biobehavioral Rev 2008; 32:611-656.
11. Maguire G, Hamasaki DI. The retinal dopamine network alters the adaptational properties of retinal ganglion cells in the cat. J Neurophysiol 1994;72:730-741.
12. Yamada M, Shigematsu Y, Umetani Y, Saito T. Dopamine decreases receptive field size of rod-driven horizontal cells in carp retina. Vision Res 1992;32:1801-1807.
13. Djamgoz MB, Hankins MW, Hirano J, Archer SN. Neurobiology of retinal dopamine in relation to degenerative states of the tissue. Vision Res 1997;37:3509-3529.
14. Harnois C, Di Paolo T. Decreased dopamine in the retinas of patients with Parkinson's disease. Invest Ophthalmol Vis Sci 1990;31:2473-2475.
15. Henn IH, Bouman L, Schlehe JS. Parkin mediates neuroprotection through activation of I{kappa}B kinase/nuclear factor-{kappa}B signaling. J Neurosci 2007;27:1868-1878.
16. Hajee ME, March WF, Lazzaro DR. Inner retinal layer thinning in Parkinson disease. Arch Ophthalmol 2009;127:737-741.
17. Inzelberg R, Ramirez JA, Nisipeanu P, Ophir A. Retinal nerve fiber layer thinning in Parkinson disease. Vision Res 2004;44: 2793-2797.
18. Maffei L, Fiorentini A, Bisti S, Hollander H. Pattern ERG in the monkey after section of the optic nerve. Exp Brain Res 1985;59: 423-425.
19. Tagliati M, Bodis-Wollner I, Yahr MD. The pattern electroretinogram in Parkinson's disease reveals lack of retinal spatial tuning. Electroencephalogr Clin Neurophysiol 1996;100:1-11.
20. Onofrj M, Ghilardi MF, Basciani M, Gambi D. Visual evoked potentials in parkinsonism and dopamine blockade reveal a stimulus-dependent dopamine function in humans. J Neurol Neurosurg Psychiatry 1986;49:1150-1159.
21. Ogiue-Ikeda M, Kawato S, Ueno S. The effect of repetitive transcranial magnetic stimulation on long-term potentiation in rat hippocampus depends on stimulus intensity. Brain Res 2003;993:222-226.
22. Peppe A, Stanzione P, Pierelli F, De Angelis D, Pierantozzi M, Bernardi G. Visual alterations in de novo Parkinson's disease: pattern electroretinogram latencies are more delayed and more reversible by levodopa than are visual evoked potentials. Neurology 1995;45:1144-1148.
23. Feigin A, Ghilardi MF, Fukuda M. Effects of levodopa infusion on motor activation responses in Parkinson's disease. Neurology 2002;59:220-226.
24. Nightingale S, Mitchell KW, Howe JW. Visual evoked cortical potentials and pattern electroretinograms in Parkinson's disease and control subjects. J Neurol Neurosurg Psychiatr 1986;49:1280-1287.
25. Calzetti S, Franchi A, Taratufolo G, Groppi E. Simultaneous VEP and PERG investigations in early Parkinson's disease. J Neurol Neurosurg Psychiatr 1990;53:114-117.
26. Zhao Y, Kerscher N, Eysel U, Funke K. D1 and D2 receptor-mediated dopaminergic modulation of visual responses in cat dorsal lateral geniculate nucleus. J Physiol (Lond) 2002;539 (Part 1): 223-238.
27. Watkins PC, Vache K, Verney SP, Muller S, Mathews A. Unconscious mood-congruent memory bias in depression. J Abnorm Psychol 1996;105:34-41.
28. Bressan RA, Costa DC, Jones HM, Ell PJ, Pilowsky LS. Typical antipsychotic drugs - D(2) receptor occupancy and depressive symptoms in schizophrenia. Schizophr Res 2002;56:31-36.
29. Hubel DH, Wiesel TN. Receptive fields of single neurones in the cat's striate cortex. J Physiol 1959;148:574-591.
30. Li M, Kuroiwa Y, Wang L. Visual event-related potentials under different interstimulus intervals in Parkinson's disease: relation to motor disability, WAIS-R, and regional cerebral blood flow. Parkinsonism Relat Disord 2005;11:209-219.
31. Bohnen NI, Minoshima S, Giordani B, Frey KA, Kuhl DE. Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia. Neurology 1999;52:541-546.
32. Devous MD, Trivedi MH, Rush AJ. Regional cerebral blood flow response to oral amphetamine challenge in healthy volunteers. J Nucl Med 2001;42:535-542.
33. Haxby JV, Hoffman EA, Gobbini MI. Human neural systems for face recognition and social communication. Biol Psychiatry 2002;51:59-67.
34. Haxby JV, Ungerleider LG, Clark VP, Schouten JL, Hoffman EA, Martin A. The effect of face inversion on activity in human neural systems for face and object perception. Neuron 1999;22:189-199.
35. Owsley C, Sloane ME. Contrast sensitivity, acuity, and the perception of "real-world" targets. Br J Ophthalmol 1987;71:791-796.
36. Elbel G, Kaufmann C, Schaefers S, Buser A, Auer D. Refractive anomalies and visual activation in functional magnetic resonance imaging (fMRI): a versatile and low-cost MR-compatible device to correct a potential confound. J Magn Reson Imaging 2002;15:101-107.